|
|
| | PROTAC HK2 Degrader-1 Basic information |
| Product Name: | PROTAC HK2 Degrader-1 | | Synonyms: | PROTAC HK2 Degrader-1;1H-Indazole-3-carboxamide, 1-[(2,4-dichlorophenyl)methyl]-N-[4-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]butyl]- | | CAS: | 3033812-84-6 | | MF: | C32H28Cl2N6O5 | | MW: | 647.51 | | EINECS: | | | Product Categories: | | | Mol File: | 3033812-84-6.mol |  |
| | PROTAC HK2 Degrader-1 Chemical Properties |
| Boiling point | 954.7±65.0 °C(predicted) | | density | 1.53±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | solubility | Ethanol: Soluble
Methanol: Soluble | | pka | 10.75±0.40(predicted) | | form | Solid | | color | Light yellow to yellow |
| | PROTAC HK2 Degrader-1 Usage And Synthesis |
| Uses | PROTAC HK2 Degrader-1 is a PROTAC consisting of Lonidamine (HY-B0486) as a target protein Hexokinase 2 (HK2) inhibitor and Thalidomide (HY-14658) as a CRBN ligand-linked PROTAC. PROTAC HK2 Degrader-1 selectively inhibits the proliferation of breast cancer cells by forming a ternary complex through the ubiquitin-proteasome system to degrade Hexokinase 2 (HK2) protein leading to mitochondrial damage and cell death. PROTAC HK2 Degrader-1 effectively inhibits breast tumor growth and reduces the colonic side effects of cisplatin for breast cancer research[1]. | | in vivo | PROTAC HK2 Degrader-1 (50 mg/kg, Intraperitoneal injection, bid, for nine times, into six-weekold female BALB/c mice) inhibits tumor growth in 4T1 tumor models[1].
PROTAC HK2 Degrader-1 (50 mg/kg, Intraperitoneal injection, bid, for nine times, six-weekold female BALB/c mice) can induce GSDME-dependent pyroptosis to realize tumor immune response and effectively inhibit breast tumor growth[1].
PROTAC HK2 Degrader-1 (Cisplatin (HY-17394) 10mg/kg, i.v., C-02 50mg/kg, i.p., 25 days, into six-weekold female BALB/c mice) can sensitize Cisplatin (HY-17394) while reducing the colon side effects of Cisplatin (HY-17394), which has potential clinical value[1]. | Animal Model: | xenograft models , into six-weekold female BALB/c mice[1] | | Dosage: | 50 mg/kg | | Administration: | Intraperitoneal injection, bid, for nine times. | | Result: | Reduced proliferation and damaged nuclei in mouse models.
Increased the levels of Cytokines IL-1β, IFN-γ, and TNF-α significantly and decreased the level of TGF-β and IL-10.
Elevated levels of cleaved-Casp-3 and GSDME-N in tumor tissues of mouse.
|
| Animal Model: | breast tumor model in mice by injecting 4T1 cells subcutaneously into six-weekold female BALB/c mice[1] | | Dosage: | Cisplatin (HY-17394) 10mg/kg, 50mg/kg | | Administration: | Cisplatin (HY-17394) (10mg/kg, i.v.), 50mg/kg, i.p., 25 days | | Result: | Inhibited tumor growth and tumor volume.
Decreased HK2 protein level, while co- treated with Cisplatin (HY-17394).
Could alleviate Cisplatin (HY-17394) aggravated colon damage.
|
| | References | [1] Sang R, et al. Degradation of Hexokinase 2 Blocks Glycolysis and Induces GSDME-Dependent Pyroptosis to Amplify Immunogenic Cell Death for Breast Cancer Therapy. J Med Chem. 2023 Jun 27. DOI:10.1021/acs.jmedchem.3c00118 |
| | PROTAC HK2 Degrader-1 Preparation Products And Raw materials |
|